Genascence Announces First Close in Series a Financing Led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board
Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced it has completed the first closing in a Series A financing led by Pacira BioSciences, Inc., totaling $10.5 million. As part of the financing, UF Innovate's Jackson Streeter, joins Genascence's board of directors.
Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis
Genascence Corporation, a clinical-stage biotechnology company developing life-changing gene therapy products for prevalent musculoskeletal diseases, announced that dosing across all three cohorts has been completed in Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA).
